HSRx 431
Alternative Names: HSRx 431; HSRx431Latest Information Update: 28 Oct 2020
At a glance
- Originator HerbalScience Group
- Developer HSRx Biopharmaceutical
- Class Antivirals
- Mechanism of Action Virus internalisation inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Chikungunya virus infections; Dengue; Zika virus infection
Most Recent Events
- 28 Oct 2020 No recent reports of development identified for preclinical development in Dengue in USA (PO)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Chikungunya-virus-infections in Unknown (PO)
- 28 Jan 2020 No recent reports of development identified for phase-I development in Zika-virus-infection in Unknown (PO)
Development Overview
Introduction
HSRx Biopharmaceutical, presumably under license from HerbalScience Group, is developing HSRx 431, a combination of berry-derived food nutrients and a generic drug, for the treatment of Zika virus infection, dengue and chikungunya virus infection. The disease-fighting food nutrients are integrated with the generic drug to create an orally delivered polyfunctional pharmaceutical product. HSRx utilizes BRILLIANT™, a technology platform developed by HerbalScience, to create its proprietary food nutrients. The food nutrients attaches to Zika virus, and prevents the virus from entering host cells. Phase I development is underway for Zika virus infection and chikungunya virus infection, and preclinical development is underway for dengue.
As at January 2020, no recent reports of development had been identified for phase-I development in Chikungunya-virus-infections in Unknown (PO), phase-I development in Zika-virus-infection in Unknown (PO).
As at October 2020, no recent reports of development had been identified for preclinical development in Dengue in USA (PO).
Company Agreements
In August 2015, HSRx acquired a portfolio of 10 proprietary OTC drug products and in-licensed 8 proprietary disease-specific pharmaceutical products from HerbalScience Group [1] .
Key Development Milestones
Phase I development is underway to evaluate the safety of HSRx 431 against Zika virus and chikungunya virus infections (HSRx Biopharmaceutical pipeline, December 2016).
HSRx Biopharmaceutical planned to seek for accelerated drug approval from the US FDA [2] .
Screening studies of HSRx 431 confirmed its effectiveness against Zika virus. Earlier, in vivo studies demonstrated the safety and effectiveness of the drug against dengue and chikungunya infections [2] .
Patent Information
HSRx Biopharmaceutical has patented HSRx 431 alone and in combination with oseltamivir (Tamiflu™) and other anti-virals [2] .
Drug Properties & Chemical Synopsis
- Route of administration PO
- Formulation unspecified
- Class Antivirals
- Target Virus internalisation
- Mechanism of Action Virus internalisation inhibitors
-
WHO ATC code
J05 (Antivirals for Systemic Use)
-
EPhMRA code
J5 (Antivirals for Systemic Use)
Table of Contents
Development Status
Summary Table
| Indication | Qualifier | Patient Segment | Phase | Countries | Route / Formulation | Developers | Event Date |
|---|---|---|---|---|---|---|---|
| Chikungunya virus infections | - | - | No development reported (I) | Unknown | PO / unspecified | HSRx Biopharmaceutical | 28 Jan 2020 |
| Dengue | - | - | No development reported (Preclinical) | USA | PO / unspecified | HSRx Biopharmaceutical | 28 Oct 2020 |
| Zika virus infection | - | - | No development reported (I) | Unknown | PO / unspecified | HSRx Biopharmaceutical | 28 Jan 2020 |
Commercial Information
Involved Organisations
| Organisation | Involvement | Countries |
|---|---|---|
| HerbalScience Group | Originator | USA |
| HerbalScience Group | Owner | USA |
| HSRx Biopharmaceutical | Licensee | USA |
Brand Names
| Brand Name | Organisations | Indications | Countries |
|---|---|---|---|
| HSRx 431 | HSRx Biopharmaceutical | Zika virus infection | USA |
Development History
| Event Date | Update Type | Comment |
|---|---|---|
| 28 Oct 2020 | Phase Change - No development reported | No recent reports of development identified for preclinical development in Dengue in USA (PO) Updated 28 Oct 2020 |
| 28 Jan 2020 | Phase Change - No development reported | No recent reports of development identified for phase-I development in Chikungunya-virus-infections in Unknown (PO) Updated 28 Jan 2020 |
| 28 Jan 2020 | Phase Change - No development reported | No recent reports of development identified for phase-I development in Zika-virus-infection in Unknown (PO) Updated 28 Jan 2020 |
| 02 Dec 2016 | Phase Change - I | Phase-I clinical trials in Chikungunya virus infections (PO) Updated 02 Dec 2016 |
| 02 Dec 2016 | Phase Change - I | Phase-I clinical trials in Zika virus infection (PO) Updated 02 Dec 2016 |
| 06 Sep 2016 | Phase Change - Preclinical | Preclinical trials in Chikungunya virus infections in USA (PO) Updated 22 Sep 2016 |
| 06 Sep 2016 | Phase Change - Preclinical | Preclinical trials in Dengue in USA (PO) Updated 22 Sep 2016 |
| 06 Sep 2016 | Phase Change - Preclinical | Preclinical trials in Zika virus infection in USA (PO) Updated 22 Sep 2016 |
| 05 Aug 2015 | Licensing Status | HSRx in-licenses 8 proprietary pharmaceutical products from HerbalScience Updated 22 Sep 2016 |
References
-
HSRx Group In-Licenses Portfolio of Novel Late-Stage Orphan and Breakthrough Combination Drugs, Acquires Ready-for-Market OTC Drugs.
Media Release -
Broad-Spectrum Antiviral Drug HSRx 431(Tm) Tests Effective Against Zika Virus.
Media Release
Adis International Ltd. Part of Springer Science+Business Media
© Springer Nature Switzerland AG